AstraZeneca PLC (BCBA:AZN)

Market Cap	305.81T
Revenue (ttm)	67.33T
Net Income (ttm)	9.89T
Shares Out	n/a
EPS (ttm)	6,326.07
PE Ratio	30.94
Forward PE	15.15
Dividend	834.84 (1.70%)
Ex-Dividend Date	Aug 8, 2025

Volume	148
Average Volume	698
Open	49,700
Previous Close	49,025
Day's Range	48,950 - 49,700
52-Week Range	34,800 - 58,050
Beta	n/a
RSI	60.93
Earnings Date	Jul 29, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Pharmaceutical Preparations
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: AZN

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD